Similar Papers

Paper Title
Journal
Date
Author
Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
Rossana Scrivo ... Valeria Riccieri
Clinical and Experimental Rheumatology | VOL. 41
Rossana Scrivo, et. al.Rossana Scrivo ... Valeria Riccieri
21 Jan 2022
Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review.
Yue Yin ... Cara Mcdermott
Journal of managed care & specialty pharmacy | VOL. 29
Yue Yin, et. al.Yue Yin ... Cara Mcdermott
01 Sep 2023
Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region.
Khalid A Alnaqbi ... Adeeba Al-Herz
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | VOL. 38
Khalid A Alnaqbi, et. al.Khalid A Alnaqbi ... Adeeba Al-Herz
25 Feb 2024
ARE WE READY FOR MULTIPLE SWITCHES BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS?
Fabio Vieira Teixeira ... Silvio Danese
Arquivos de gastroenterologia | VOL. 61
Fabio Vieira Teixeira, et. al.Fabio Vieira Teixeira ... Silvio Danese
01 Jan 2024
View more papers

More From: Value in Health

Paper Title
Journal
Date
Author
Table of Contents
-
Value in Health | VOL. 28
--
01 Feb 2025
Editorial Board
-
Value in Health | VOL. 28
--
01 Feb 2025
Table of Contents
-
Value in Health | VOL. -
--
01 Jan 2025
Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force
Siobhan Botwright ... Yot Teerawattananon
Value in Health | VOL. -
Siobhan Botwright, et. al.Siobhan Botwright ... Yot Teerawattananon
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.